Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90

Tallen, Gesche; Ratei, Richard; Mann, Georg; Kaspers, Gertjan J. L.; Niggli, Felix; Karachunsky, A. I.; Ebell, Wolfram; Escherich, Gabriele; Schrappe, Martin; Klingebiel, Thomas; Fengler, R.; Henze, Günter; Stackelberg, Arend von

doi:10.1200/jco.2009.25.1983

Cited by 275 publications

(267 citation statements)

References 37 publications

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…15,16 Patients with relapsed ALL were treated according to the risk stratification of BFM relapses protocols. 17 For AML patients in CR1, HSCT was recommended for all patients with monosomy 5 or 7, translocation t(6,9) and mixed lineage leukemia rearrangement, except for translocation t(9,11) with related or unrelated donors, and was performed in other cases with matched sibling donors (MSDs) only, except for patients with translocation t (8,21). 18 All AML relapses were indications to transplant after CR2 was achieved.…”

Section: Patients and Methods Patientsmentioning

confidence: 99%

Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis

Bleyzac

Cuzzubbo

Rénard

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

There is currently a major concern regarding the optimal immunosuppression therapy to be administered after hematopoietic stem cell transplantation (HSCT) to reduce both the toxicity of GvHD and the rate of relapse. We report the outcome of high-risk leukemia children transplanted with a new way of managing cyclosporine (CsA)-based GvHD prophylaxis. A total of 110 HSCT in 109 ALL or AML children who received CsA without mycophenolate or methotrexate in matched related as well as in matched or mismatched unrelated stem cell transplantation were included. CsA dosage regimens were individualized to obtain specific trough blood concentrations values. The incidences of grade I-II and III-IV acute GvHD were 69.1% and 1.8%, respectively, and 8.4% for chronic GvHD. GvHD was neither more frequent nor severe in unrelated than in related HSCT. GvHD occurred in 87% of patients with a mean CsA trough concentration ⩽ 120 ng/mL versus 43% with concentration 4120 ng/mL (Po 0.0001). Five-year disease-free survival (DFS) and overall survival were 78% and 83.6%, respectively. DFS was 76.9% for ALL and 80.4% for AML patients. There was no difference in DFS between matched siblings and matched unrelated or mismatched unrelated HSCT. DFS in patients with minimal residual disease (MRD) ⩾ 10 − 3 and in those with MRD o 10 − 3 before SCT was comparable. Our results indicate that a GvHD prophylaxis regimen based on CsA without mycophenolate or methotrexate is safe and effective whatever the donor compatibility is. These results suggest that GvL effect may be enhanced by this strategy of GvHD prophylaxis.

show abstract

Section: Patients and Methods Patientsmentioning

confidence: 99%

Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis

Bleyzac

Cuzzubbo

Rénard

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…The outcome for many of these children remains poor; however several characteristics have been identified, which in turn suggest therapeutic options. Site of relapse is important with patients having extra-medullary relapse fairing better than those with marrow involvement [54][55][56][57]. Children relapsing early (<18 months from start of treatment) due particularly poorly while late relapses (>36 months) have better outcomes.…”

Section: Treatment Of Relapsed Pallmentioning

confidence: 99%

Untitled

2017

HTIJ

View full text Add to dashboard Cite

ClassificationEarly classification schema for pALL relied on criteria using the French-American-British (FAB) system, based on morphology and other patient characteristics. The FAB system is no longer AbstractProgress in the understanding and treatment of pediatric acute lymphoblastic leukemia over the past 60 years has been remarkable and it is now expected that 80-85% of children diagnosed will be cured of this disease. This review article discusses risk factors, classification, presentation, risk groups, treatment, outcome, and long-term complications of therapy. Pediatric cancer studies serve as a model for national and international group cooperation to treat uncommon diseases.

show abstract

“…Программы лечения рецидивов лимфобластных лимфом из клеток-предшественников (ЛБЛ) анало-гичны применяемым при остром лимфобластном лейкозе (ОЛЛ), и 10-летняя ОВ составляет 8,7-30 % [10,11]. С целью возможного повышения эффектив-ности терапии в программы лечения стали включать-ся новые цитостатические агенты.…”

unclassified

Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas

Валиев¹

2018

Onkogematologiâ

View full text Add to dashboard Cite

Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90

Cited by 275 publications

References 37 publications

Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis

Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis

Untitled

Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas

Contact Info

Product

Resources

About